Improving Shingrix Vaccination Among US Veterans Receiving Immunosuppression

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT06596148
Status
Enrolling By Invitation

Conditions

  • Immunosuppresion

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Access to Shingrix dashboard — OTHER
    The investigators will build and grant access to a clinical dashboard that exists behind the VA firewall. The dashboard will identify Veterans from each VA facility who are receiving immunosuppressants (prescribed via the VA). The dashboard will also provide information about the number of Shingrix vaccines each patient has received (which have been documented within the VA electronic health record). VA clinicians will have access to view information about patients based on their VA electronic health record permissions.

Study Details

The goal of this wait-list control trial is to learn if having access to a new dashboard displaying information about immunosuppressed Veterans missing vaccinations for Shingrix can improve Shingrix vaccination rates at VA facilities. The main question\[s\] it aims to answer is: Will vaccination rates improve more rapidly for facilities with access to the dashboard compare to facilities without access? VA facility personnel will be granted access to the dashboard and outcomes (vaccination rates) will be measured using electronic health record data.

Key Dates

Start date
Sep 16, 2024
Status verified
Apr 2025
Primary completion
Mar 31, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
130 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: Early dashboard access
    The early dashboard access arm will receive access to the Shingrix dashboard as soon as the study begins.
  • Other: Wait list control arm
    The wait list control arm will receive no intervention for 6-9 months; after this period, this arm will also receive access to the Shingrix dashboard.

Primary Outcome Measure

Percentage of patients with at least 1 Shingrix vaccine documented, by facility [ Time Frame: From enrollment until end of follow up at 18 months. ]

Locations (1)

FacilityCityStateZIPSite coordinators
San Francisco VASan FranciscoCalifornia94121-

Find similar trials in San Francisco, CA

By research site
San Francisco VA· San Francisco, CA

Related Studies